Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long NVO ETF

17.59
+2.8919.66%
Pre-market: 19.361.77+10.07%08:03 EST
Volume:1.02M
Turnover:17.13M
Market Cap:49.57M
PE:- -
High:17.61
Open:16.70
Low:16.36
Close:14.70
52wk High:105.60
52wk Low:14.59
Shares:2.82M
Float Shares:2.80M
Volume Ratio:0.62
T/O Rate:36.36%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novo Nordisk Sues Telehealth Firm Over $49 Weight-Loss Pills

Deep News
·
Just now

Novo Nordisk Sues Hims & Hers for Alleged Patent Infringement Over 'Knock-Off' Wegovy, Ozempic

MT Newswires Live
·
45 mins ago

3 Things That Can Ease Stock Market Nerves as Crucial Jobs Report Looms -- Barrons.com

Dow Jones
·
1 hour ago

Novo Nordisk Shares Surge as Rival Abandons Low-Cost Wegovy Copycat Plan

Deep News
·
1 hour ago

Bank of America flags a really big risk to bonds - the stock market

Dow Jones
·
1 hour ago

Hims & Hers Stock Plunges 15%. Why Losing the Novo Wegovy Battle Is a Blow. -- Barrons.com

Dow Jones
·
2 hours ago

Barclays Remains a Hold on Novo Nordisk (0QIU)

TIPRANKS
·
3 hours ago

HIMS Stock Drops, NVO Jumps after Hims & Hers Halts Selling $49 Wegovy Copy

TIPRANKS
·
3 hours ago

Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

Dow Jones
·
4 hours ago

Novo Nordisk Faces Price War in Competitive Anti-Obesity Drug Market with No Relief in Sight

Deep News
·
5 hours ago

Gartner, Stellantis, And Novo Nordisk Are Among Top 10 Large Cap Losers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?

Benzinga
·
Yesterday

Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny -- Barrons.com

Dow Jones
·
Yesterday

The Weight-Loss Price Wars Are Breaking Big Pharma's Business Model -- Heard on the Street -- WSJ

Dow Jones
·
Feb 07

Review -- Barron's

Dow Jones
·
Feb 07

Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges. -- Barrons.com

Dow Jones
·
Feb 07

Health Care Up as Novo Nordisk Recoups Some Losses -- Health Care Roundup

Dow Jones
·
Feb 07

TrumpRx Is Here. Most People Won't Benefit. -- Barrons.com

Dow Jones
·
Feb 07

Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill

Dow Jones
·
Feb 07

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires Live
·
Feb 07

European Markets Gain Amid Volatility as Novo Nordisk Rebound Offsets Stellantis Plunge

Deep News
·
Feb 07